Compare CAPL & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | AURA |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | 113 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 772.3M |
| IPO Year | 2012 | 2021 |
| Metric | CAPL | AURA |
|---|---|---|
| Price | $21.60 | $7.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 50.2K | ★ 772.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,869,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $85.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.61 | $4.73 |
| 52 Week High | $23.34 | $9.54 |
| Indicator | CAPL | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 48.84 |
| Support Level | $21.53 | $5.94 |
| Resistance Level | $23.08 | $7.68 |
| Average True Range (ATR) | 0.71 | 0.35 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 6.04 | 25.90 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.